Provider Briefing: Angeliq 0.25/0.5 28 Day in 2026

If your patients on Angeliq 0.25/0.5 28 Day (Drospirenone 0.25 mg / Estradiol 0.5 mg) have been reporting difficulty filling prescriptions, they're not exaggerating. While Angeliq is not currently on the FDA's official drug shortage list, persistent pharmacy-level supply issues are creating real treatment disruptions for women on this niche combination HRT.

This briefing covers the current availability picture, prescribing considerations, and practical tools to help your patients maintain uninterrupted therapy.

Timeline: How We Got Here

Angeliq was first approved by the FDA in September 2005 at the 0.5/1 mg strength, manufactured by Berlex (later acquired by Bayer). The lower-dose 0.25/0.5 mg formulation received FDA approval in February 2012, targeting women who could achieve adequate symptom relief with a lower hormone exposure.

Key developments affecting current availability:

• 2012: FDA approval of the 0.25/0.5 mg strength (lower-dose formulation)
• October 2025: Novast Labs receives FDA approval for a generic version of the 0.5/1 mg strength — but not the 0.25/0.5 mg strength
• 2026: No generic competition exists for the 0.25/0.5 mg formulation. Patent protection extends until October 2031.

The net result: Bayer remains the sole manufacturer of Angeliq 0.25/0.5, and the product's relatively small market share means many pharmacies don't maintain routine stock.

Prescribing Implications

When patients can't fill their Angeliq 0.25/0.5 prescriptions promptly, the clinical consequences can include:

• Symptom recurrence: Vasomotor symptoms can return within days of HRT discontinuation, significantly impacting quality of life
• Patient frustration and non-adherence: Repeated stock-outs erode patient confidence in the medication and the healthcare system
• Unplanned therapy switches: Patients may request emergency switches to whatever HRT is available, without optimal clinical matching

Key prescribing considerations specific to Angeliq 0.25/0.5:

• Hyperkalemia risk: Drospirenone has antimineralocorticoid activity. Monitor serum potassium during the first treatment cycle in patients taking ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, or potassium supplements. This is particularly important and differentiates Angeliq from most other combination HRT products.
• Renal/hepatic contraindication: Angeliq is contraindicated in patients with renal impairment, hepatic impairment, or adrenal insufficiency — again due to the Drospirenone component
• CYP3A4 interactions: Strong CYP3A4 inhibitors (Ketoconazole, Itraconazole, Clarithromycin) can increase Drospirenone levels. Consider monitoring in patients on long-term strong CYP3A4 inhibitors. For a detailed review, see our drug interactions guide.

Current Availability Picture

As of March 2026:

• FDA shortage status: Not listed
• Manufacturer: Bayer Healthcare continues active production and distribution
• Generic status (0.25/0.5 mg): No generic available. Patent expires October 2031.
• Generic status (0.5/1 mg): Generic approved October 2025 (Novast Labs). Commercial availability may be limited initially.
• Practical availability: Inconsistent at the pharmacy level, particularly at large chain pharmacies that use automated inventory systems favoring high-volume products

Cost and Access Considerations

Without generic competition, Angeliq 0.25/0.5 remains one of the more expensive combination HRT options:

• Average cash price: $224-$234 for a 28-day supply
• With discount coupons (GoodRx): As low as $186/month
• Bayer Savings Card: Commercially insured patients may pay as little as $0 (up to $125/month savings). Uninsured patients receive up to $75 off.
• Bayer Patient Assistance Foundation: Provides Angeliq at no cost to eligible low-income patients

Many insurance formularies cover Angeliq but may require prior authorization or step therapy (typically trying generic Prempro or Activella first). For a comprehensive cost guide to share with patients, see How to Save Money on Angeliq.

Tools and Resources for Your Practice

Help Patients Locate Stock

Medfinder for Providers allows you to check real-time pharmacy availability for Angeliq 0.25/0.5 28 Day and direct patients to pharmacies with current stock. This can be integrated into your prescribing workflow to avoid sending prescriptions to pharmacies that can't fill them.

Pre-identify Alternative Pharmacies

Independent pharmacies and specialty pharmacies tend to have more flexible ordering relationships with wholesalers. Consider maintaining a list of local independent pharmacies that are willing to special-order Angeliq for your patients.

Proactive Prescription Management

For patients on Angeliq, consider writing prescriptions with refills and encouraging auto-refill enrollment. Advise patients to initiate refills 10-14 days before running out. For a practical guide to share with patients, see our provider's guide to helping patients find Angeliq.

Looking Ahead

The availability situation for Angeliq 0.25/0.5 is unlikely to improve significantly before 2031, when the patent expires and generic competition may enter the market. In the meantime, the most effective approach is a combination of proactive prescription management, patient education about pharmacy options, and having a clear alternative HRT plan ready if supply disruptions occur.

The approval of a generic for the 0.5/1 mg strength in 2025 is a positive signal that generic manufacturers see commercial potential in the Drospirenone/Estradiol combination, which may accelerate interest in the lower-dose formulation once patent protection ends.

Final Thoughts

Angeliq 0.25/0.5 28 Day occupies an important niche in the HRT landscape — its Drospirenone component offers unique antimineralocorticoid and antiandrogenic benefits that other combination products don't provide. For patients who do well on this formulation, maintaining access is clinically meaningful.

By leveraging tools like Medfinder, proactively managing prescriptions, and having alternative strategies ready, providers can help ensure their patients don't experience treatment gaps due to supply constraints.